001     127475
005     20240228140930.0
024 7 _ |a 10.1002/gcc.22271
|2 doi
024 7 _ |a pmid:26173806
|2 pmid
024 7 _ |a 1045-2257
|2 ISSN
024 7 _ |a 1098-2264
|2 ISSN
024 7 _ |a altmetric:4284845
|2 altmetric
037 _ _ |a DKFZ-2017-03498
041 _ _ |a eng
082 _ _ |a 570
100 1 _ |a Schöttker, Ben
|0 P:(DE-He78)c67a12496b8aac150c0eef888d808d46
|b 0
|e First author
|u dkfz
245 _ _ |a Discovery of a novel epigenetic cancer marker related to the oxidative status of human blood.
260 _ _ |a New York, NY
|c 2015
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1521712215_15724
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Long-lasting oxidative stress exposure may lead to relatively stable epigenetic modifications of the DNA in order to activate anti-oxidative defence mechanisms. Oxidative stress related DNA methylation may therefore be associated (causally or as a by-product) with cancer. We measured derivatives of reactive oxygen metabolites (D-ROM), total thiol levels (TTL) and DNA methylation with the Illumina Infinium 450K BeadChip in three samples of German individuals aged ≥50 years: n = 1,000 ESTHER study baseline participants (DNA methylation only), n = 99 ESTHER eight-year follow-up participants and n = 142 participants of the BLITZ study. The correlation coefficient of methylation at cg10342304 and D-ROM in the ESTHER 8-year follow-up sample (r = -0.427; P = 1 × 10(-5)) was replicated with a P-value indicating statistical significance after correction for multiple testing in the BLITZ sample (r = -0.192; P = 0.022). The association was robust to adjusting for potential confounders. In the ESTHER baseline sample, the hazard ratio for cancer development in 11 years of follow-up comparing bottom and top quartile of DNA methylation at cg10342304 was 1.86 (95%-confidence-interval 1.01-3.43). In summary, this first epigenome-wide screening and replication study with oxidative status markers observed a negative correlation of D-ROM levels and DNA methylation at cg10342304 in two independent cohorts. This CpG site is located in the body region of the nucleoredoxin gene. The nucleoredoxin protein is a redox-dependent inhibitor of the Wnt/ß-catenin signaling pathway, a well-characterized cancer pathway. If the observed CpG-cancer association can be successfully replicated by other studies, this epigenetic marker could be an interesting biomarker of cancer risk.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Biomarkers, Tumor
|2 NLM Chemicals
650 _ 7 |a Reactive Oxygen Species
|2 NLM Chemicals
700 1 _ |a Zhang, Yan
|0 P:(DE-He78)6a8f87626cb610618a60d742677284cd
|b 1
|u dkfz
700 1 _ |a Heiss, Jonathan
|0 P:(DE-He78)d3e4e449f4ed4d38e6ec44362e89dbc8
|b 2
|u dkfz
700 1 _ |a Butterbach, Katja
|0 P:(DE-He78)7ca7eafba864e5c3ebb7598149380452
|b 3
|u dkfz
700 1 _ |a Jansen, Eugène H J M
|b 4
700 1 _ |a Bewerunge-Hudler, Melanie
|0 P:(DE-He78)7999346780553d7fab7ba69d5afdfa71
|b 5
|u dkfz
700 1 _ |a Saum, Kai-Uwe
|0 P:(DE-He78)97343bbd9545a4b87574e74329dabfd1
|b 6
|u dkfz
700 1 _ |a Holleczek, Bernd
|b 7
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 8
|e Last author
|u dkfz
773 _ _ |a 10.1002/gcc.22271
|g Vol. 54, no. 9, p. 583 - 594
|0 PERI:(DE-600)1492641-6
|n 9
|p 583 - 594
|t Genes, chromosomes & cancer
|v 54
|y 2015
|x 1045-2257
909 C O |o oai:inrepo02.dkfz.de:127475
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)c67a12496b8aac150c0eef888d808d46
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)6a8f87626cb610618a60d742677284cd
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)d3e4e449f4ed4d38e6ec44362e89dbc8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)7ca7eafba864e5c3ebb7598149380452
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)7999346780553d7fab7ba69d5afdfa71
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)97343bbd9545a4b87574e74329dabfd1
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2015
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b GENE CHROMOSOME CANC : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l Klinische Epidemiologie und Alternsforschung
|x 0
920 1 _ |0 I:(DE-He78)W110-20160331
|k W110
|l Microarray Unit
|x 1
920 1 _ |0 I:(DE-He78)G110-20160331
|k G110
|l Präventive Onkologie
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)W110-20160331
980 _ _ |a I:(DE-He78)G110-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21